Svai Sanford's departure as Chief Financial Officer of Rani Therapeutics Holdings, Inc. was reported; the filing names no successor. As of November 6, 2026, Rani Therapeutics Holdings, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 15, 2026 to August 4, 2026, naming 1 appointment and 1 departure (Form 8-K, May 15, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Rani Therapeutics Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Michelle Gilson · 8-K, 2026-08-04
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-30
- · In / out: Out · Person: Svai Sanford · Role: Chief Financial Officer · 8-K, 2026-05-15
Rani Therapeutics Holdings, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-15 to 2026-08-04. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Rani Therapeutics Holdings, Inc. files it.
Also on the record for Rani Therapeutics Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G/A, by Vanguard Capital Management | 4.49% of the class | 5%+ stakes | Source |
| May 28, 2026 | Stake report, Schedule 13D/A, by Samsara BioCapital, L.P. | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by SymBiosis Capital Partners, LLC | 4.4% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.12% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G, by AWM Investment Company, Inc. | 9.9% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G, by SymBiosis Capital Partners, LLC | 6.5% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G, by The Vanguard Group | 5.23% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| November 10, 2025 | Form D, private offering | $60.26M sold | Form D page | Source |
| October 30, 2025 | Stake report, Schedule 13D, by Samsara BioCapital, L.P. | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Rani Therapeutics Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Rani Therapeutics Holdings, Inc. and the records around it.
Rani Therapeutics Holdings, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Nov 2025
- Who owns it
Companies that share a holder
- SymBiosis Capital Partners, LLC also filed stake reports on 1 other company: Generation Bio Co. (Nov 2025)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), KALARIS THERAPEUTICS, INC. (May 2026)
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
Watch Rani Therapeutics Holdings, Inc.
Get an email when Rani Therapeutics Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Rani Therapeutics Holdings, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Rani Therapeutics Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rani Therapeutics Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 19 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-04 | In | 8-K, 2026-08-04 | |||
| 2026-06-30 | Reported | not named in the filing | 8-K, 2026-06-30 | ||
| 2026-05-15 | Out | Chief Financial Officer | 8-K, 2026-05-15 |
Who leads Rani Therapeutics Holdings, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Svai Sanford, departure reported (filed 2026-05-15). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Rani Therapeutics Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Rani Therapeutics Holdings, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Rani Therapeutics Holdings, Inc.Every change, in the filing's words
Appointed: Michelle Gilson
Director Appointment On August 1, 2026, Michelle Gilson was appointed to the Board, effective immediately, until the earlier of the Company's next annual meeting of stockholders, the appointment and qualification of her successor, or her death, resignation, or removal.
- In addition, Ms. Gilson was appointed as chair of the Audit Committee.
- Michelle Gilson, age 34, has served as the Chief Financial Officer of Arcellx, Inc., a biotechnology company, from May 2022 through its acquisition by Gilead Sciences, Inc. in April 2026.
- From 2018 to 2022, Ms. Gilson served as a Senior Biotechnology Equity Research Analyst at Canaccord Genuity Group Inc., a financial services firm, most recently as a Managing Director.
- She served as a Senior Associate at Jefferies LLC, an investment banking firm, from 2017 to 2018, an Associate at Nomura Group, a financial securities service firm from 2016 to 2017, an Associate Director at Oppenheimer & Co., Inc., an investment bank and financial services company from 2015 to 2016, and an Analyst at Goldman Sachs, an investment bank and financial services company, from 2014 to 2015, covering healthcare and biotechnology companies.
- Ms. Gilson holds a B.S. in Business Administration from the University of Southern California.
- The Indemnity Agreement provides, among other things, that the Company will indemnify Ms. Gilson, under the circumstances and to the extent provided therein, for certain expenses which she may be required to pay in connection with certain claims to which she may be made a party by reason of her service to the Company as a director and otherwise to the fullest extent under applicable law.
Reported
On June 29, 2026, Rani Therapeutics Holdings, Inc. (the "Company") announced the appointment of Nicholas M. Maestas as the Company's Chief Financial Officer (principal financial officer and principal accounting officer) effective as of June 29, 2026.
- Mr. Maestas succeeds Svai Sanford as the Company's Chief Financial Officer, who the Company previously announced would be stepping down upon the appointment of his successor.
- Mr. Maestas, age 46, most recently served as the Chief Financial Officer and Head of Corporate Strategy of Tempest Therapeutics, Inc., a biotechnology company ("Tempest") from January 2025 until June 2026, having previously served as Vice President, Finance and Strategy of Tempest from July 2021 through December 2024, and as its Corporate Secretary since September 2022.
- From July 2019 to July 2021, Mr. Maestas served as the head of FP&A and strategic finance at Alector, a biopharmaceutical company.
- From November 2014 to July 2019, Mr. Maestas served in a variety of roles at Immune Design, an oncology immunotherapy company that was acquired by Merck & Co in 2019, including as Senior Director, Corporate Development & Operations from January to July 2019 and Director, Corporate Development & Operations from January 2017 to December 2018.
- Mr. Maestas received a B.A. in Molecular and Cell Biology from the University of California, Berkeley and an M.B.A. from The Wharton School, University of Pennsylvania.
- Pursuant to an offer letter, dated June 24, 2026, Mr. Maestas' annual base salary will be $500,000 and he will be eligible to earn an annual bonus with a target equal to 75% of his base salary.
Departing: Svai Sanford, Chief Financial Officer
On May 12, 2026, Svai Sanford, the Company's Chief Financial Officer, advised the Company that he will resign from his position following the appointment of his successor.
- In the interim, Mr. Sanford has agreed to continue serving as Chief Financial Officer during to ensure continuity and support an orderly transition of responsibilities until a successor is appointed or until an earlier date as may be mutually agreed between the Company and Mr. Sanford.
- Mr. Sanford's departure is not the result of any disagreement with the Company on any matter relating to the Company's financial operations, policies or practices.
- The Company has commenced a search for a successor Chief Financial Officer.
- Mr. Sanford and the Company have entered into a transition and separation agreement, dated May 15, 2026 (the "Separation Agreement").
- The Separation Agreement provides that, in exchange for executing a general release of claims in favor of the Company, after his departure, Mr. Sanford will receive his base salary of $491,400 for nine months following his departure, as well as COBRA premiums for nine months.
- All of Mr. Sanford's unvested stock options and restricted stock units for shares of the Company's Class A common stock shall accelerate and fully vest upon as of his departure date, and Mr. Sanford will have up to one year to exercise all of his stock options for shares of the Company's Class A common stock.
Tools for this story
Each opens in a new tab, filled in for Rani Therapeutics Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.